ADX-71441 explained

ADX-71441 is a GABA_B receptor positive allosteric modulator currently being investigated as a potential treatment for anxiety, epilepsy, pain and other conditions.

Therapeutic potential

ADX-71441 has been shown to reduce alcohol consumption.^[1] This result was observed in both alcohol dependent and non-dependent animals.^[2]

There were also trials about nicotine addiction, which showed positive results: ADX-71441 was able to decrease some withdrawal symptoms of nicotine withdrawal.^[3]

This compound has also been shown to reduce anxiety in people with PTSD.^[4]

Experiments have shown that this compound was able to decrease hypersensitivity to pain in mice, Guinea pigs and rats.

ADX-71441 has been shown to have less tolerance and side effects than direct GABA_B agonists, such as baclofen.

Web site: Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Chronic Alcohol Dependence . 2024-02-03 . Addex therapeutics . en.
Augier . Eric . Dulman . Russell S. . Damadzic . Ruslan . Pilling . Andrew . Hamilton . J. Paul . Heilig . Markus . August 2017 . The GABAB Positive Allosteric Modulator ADX71441 Attenuates Alcohol Self-Administration and Relapse to Alcohol Seeking in Rats . Neuropsychopharmacology . en . 42 . 9 . 1789–1799 . 10.1038/npp.2017.53 . 28294133 . 5520784 . 1740-634X.
Web site: Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction . 2024-02-03 . Addex therapeutics . en.
2017. The drug candidate, ADX71441, is a novel, potent and selective positive allosteric modulator of the GABA_B receptor with a potential for treatment of anxiety, pain and spasticity . 10.1016/j.neuropharm.2016.11.016 . Kalinichev . Mikhail . Girard . Françoise . Haddouk . Hasnaà . Rouillier . Mélanie . Riguet . Eric . Royer-Urios . Isabelle . Mutel . Vincent . Lütjens . Robert . Poli . Sonia . Neuropharmacology . 114 . 34–47 . 27889489 . 36606154 .